I'll analyze Danaher's segment revenue mix over time. Let me start by loading their revenue data.Total revenue is available. Now let me search SEC filings for segment-level revenue breakdown.I have 2021–2024 segment data. I need 2020 for a 5-year timeline and the latest 2025 figure.I now have all the data I need. Let me build the chart and table.

Important context: In 2020, Danaher's segments were Life Sciences, Diagnostics, and Environmental & Applied Solutions. The "Biotechnology" segment was created later (in connection with the Cytiva acquisition and a 2022 reorganization). For 2020, the bioprocessing businesses lived within Life Sciences. I'll show the 2021–2025 data on the current three-segment structure (Biotechnology, Life Sciences, Diagnostics), and note the 2020 figure uses the prior structure.

Now let me build the chart DataFrame and present.

Loading chart...Danaher Segment Revenue Mix Over Time

All figures in $ millions (GAAP, as reported). 2020 reflects the prior three-segment structure (Life Sciences / Diagnostics / Environmental & Applied Solutions); the Biotechnology segment was created in 2021–2022 from former Life Sciences bioprocessing operations (Cytiva + Pall bioprocessing).

Segment	FY20	FY21	FY22	FY23	FY24	FY25
Biotechnology	n/a	8,570	8,758	7,172	6,759	7,293
Life Sciences	10,576	6,388	7,036	7,141	7,329	7,334
Diagnostics	7,403	9,844	10,849	9,577	9,787	9,941
Total (Continuing Ops)	22,284	24,802	26,643	23,890	23,875	24,568

Mix (% of total continuing-ops revenue)

Segment	FY21	FY22	FY23	FY24	FY25
Biotechnology	34.6%	32.9%	30.0%	28.3%	29.7%
Life Sciences	25.8%	26.4%	29.9%	30.7%	29.9%
Diagnostics	39.7%	40.7%	40.1%	41.0%	40.5%

Key takeaways

• Diagnostics is the largest segment and has been the most stable share contributor at ~40% across the post-COVID period. Sales peaked at $10.85B in FY22 (COVID test cycle), dipped in FY23 ($9.58B), and have since rebuilt gradually to $9.94B in FY25.
• Biotechnology sales declined from the FY22 peak of $8.76B to $6.76B in FY24 (-23% over two years) on post-COVID bioprocessing destocking and weak emerging-biotech funding. FY25 turned positive (+7.9% YoY to $7.29B) led by bioprocessing consumables.
• Life Sciences scaled from $6.39B in FY21 to $7.33B in FY25, gaining roughly 4 points of mix share over the period as Abcam (closed late 2023) and IDT/Aldevron added consumables scale. FY25 was essentially flat as funding headwinds at emerging-biotech and academic customers offset equipment strength.
• Total revenue bottomed at $23.88B in FY23-24 (vs. $26.64B FY22 peak) and re-grew modestly to $24.57B in FY25 (FX tailwind +0.5%; core sales +2.0%).